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Abstract
The objective of this study was to evaluate the human health impact of using fluoroquinolones to treat bovine
respiratory disease (BRD) in dairy heifers less than 20 months of age. Specifically, this study quantified the
probability of persistent symptoms in humans treated with a fluoroquinolone, for a fluoroquinolone-resistant
Campylobacter, Salmonella, or multidrug-resistant (MDR) Salmonella infection acquired following the con-
sumption of ground beef. To comply with a Food and Drug Administration requirement for approval of
enrofloxacin use in dairy heifers, a binomial event tree was constructed following Food and Drug Adminis-
tration guidance 152. Release was estimated from the slaughter of dairy cattle carrying fluoroquinolone-
resistant bacteria attributed to the proposed use in dairy heifers. For exposure, human foodborne exposure to
Campylobacter, Salmonella, and MDR Salmonella after consumption of ground beef was estimated. The conse-
quence assessment included illness, fluoroquinolone treatment, and persistent symptoms in patients treated
with a fluoroquinolone. Using best available data to estimate the parameters and probabilities of each event,
stochastic simulation was used to represent uncertainty and variability in many of the parameters. A scenario
analysis was performed to evaluate the uncertainty of the following parameters: (1) probability of resistance
development in treated animals, (2) portion of illnesses attributable to ground beef, and (3) probability of
persistent symptoms in patients 18 years of age and over treated with a fluoroquinolone. The population at
risk was restricted to people 18 years of age and over, as fluoroquinolones are not labeled for treatment of
gastroenteritis in children. The mean annual increased risk of cases in the U.S. population (18 years of age and
over) where compromised fluoroquinolone treatment resulted in persistent symptoms was estimated to be 1 in
61 billion (one case every 293 years) for Salmonella, 1 in 33 billion (one case every 158 years) for MDR
Salmonella, and 1 in 2.8 billion (one case every 13 years) for Campylobacter.
Introduction
The vast majority of foodborne Salmonella andCampylobacter infections result in relatively mild, self-
limiting illness requiring no treatment (CDC MMWR, 2004).
However, some patients are hospitalized and, ignoring co-
morbidity, about 0.05% and 0.006%develop fatal disease from
Salmonella and Campylobacter infections, respectively (Kennedy
et al., 2000). Antimicrobial resistance may limit treatment op-
tions for those few developing severe illness (CDC MMWR,
2004). There is concern that agricultural use of antimicrobial
drugs may increase the occurrence of resistance and thereby
adversely affect human health. The potential human health
risks of antimicrobial use in livestock cannot be generalized
and depend on the specific drug in question, administration
practices, production system, and pathogens involved.
Risk assessments have become an integral part of the
approval process for antimicrobial drugs used in food-
producing animals, and are required by the U.S. Food
and Drug Administration’s (FDA) Center for Veterinary
Medicine (CVM) to evaluate the Human Food Safety of a
proposed approval. While FDA guidelines outline a quali-
tative approach (FDA CVM, 2003a), we used a quantitative,
event tree approach. A similar approach has previously
been used to evaluate macrolide use in food animals (Hurd
et al., 2004).
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Enrofloxacin (Baytril100; Bayer HealthCare LLC, Animal
Health; Shawnee Mission, KS) was approved by the CVM in
July 1998 for use in cattle for the treatment of bovine respi-
ratory disease associated with Mannheimia haemolytica, Pas-
teurella multocida, andHistophilus somni. The original approval
excluded the use of enrofloxacin in cattle intended for dairy
production.
The objective of this studywas to evaluate and quantify the
human health risk of a new use for a commercially available
fluoroquinolone in dairy heifers <20 months of age. The
specific use would be only for treatment of respiratory disease
in females <20 months old, as they are nonlactating.
Materials and Methods
A probabilistic risk assessment was conducted using a bi-
nomial event tree organized in accordance with the steps
described in the U.S. FDA’s Guidance Document (GD) 152,
which include (1) release, (2) exposure via the foodborne
route, and (3) consequence. For release, the emergence or se-
lection of resistant bacteria attributed to the proposed use of
enrofloxacin in dairy heifers was estimated. For exposure,
human foodborne exposure to Campylobacter, Salmonella, and
multidrug-resistant (MDR) Salmonella after consumption of
ground beef was estimated. The consequence assessment in-
cluded illness, fluoroquinolone treatment, and persistent
symptoms in patients treated with a fluoroquinolone. Avail-
able data were used to estimate the parameters and distri-
butions of each event. The population at risk was restricted to
18 years of age and over, as fluoroquinolones are not labeled
for use to treat gastroenteritis in children.
Antimicrobial susceptibility testing results
Antimicrobial resistance guidelines used in this study were
based on the laboratory results taken from published peer-
reviewed journal articles referenced in this article. When
testing details were provided, the laboratories conducting the
tests followed the procedures used in the National Anti-
microbial Resistance Monitoring System (NARMS) testing
program and were current for the time of their studies. The
interpretive criterion for susceptibility testing Salmonella spp.
for fluoroquinolones is 1, 2, and 4mg=mL for susceptible,
intermediate, and resistant isolates, respectively. The same
interpretive criterion is used for Campylobacter even though
there are no approved CLSI=NCCLS laboratory standards
(FDA CVM, 2003b, 2003c; USDA ARS, 2003).
Modeling approach
A quantitative, event tree modeling approach was used for
this risk assessment. Event tree models typically identify se-
quences of events leading from an initiating event (animal
antimicrobial use) to human health risk. In this model, the
probabilities were modeled as either deterministic or sto-
chastic parameters, depending on data reliability and avail-
ability. Deterministic parameters were represented by single,
discrete point estimates, whereas stochastic parameters were
represented by statistical distributions. Monte Carlo simula-
tions were performed to create probability distributions of the
model outcome (i.e., the ‘‘risk’’). The model was built, and
simulations performed using Microsoft Excel 2002 (Micro-
soft Corp., Redmond, WA) and @Risk 4.5 (Palisade Corp.,
Ithaca, NY). The outcome was defined as fluoroquinolone-
resistant Salmonella or Campylobacter infections in humans
resulting in persistent symptoms after physician treatment
with fluoroquinolones.
Three unique features of this model were (1) potential
transfers of fluoroquinolone-resistant foodborne bacteria
from fluoroquinolone-treated dairy heifers to untreated
cows and heifers within a farm, due to commingling; (2)
potential transfers of fluoroquinolone-resistant foodborne
bacteria from dairy heifers originating from farms with
fluoroquinolone-treated dairy heifers to other farms that may
acquire those animals, and that may as a consequence harbor
fluoroquinolone-resistant foodborne bacteria; and (3) cross-
contamination, during the mixing process, of ground beef
containing fluoroquinolone-resistant pathogens originating
from treated dairy heifers <20 months of age with ground
beef free of fluoroquinolone-resistant foodborne pathogens.
The model simulated the effect of potential resistance
transfer between animals and farms, regardless of the mech-
anism of resistance development within the treated animal. It
modeled the spread between animals by allowing untreated
herd mates to develop resistance and by modeling the
movement of treated animals to other herds not using enro-
floxacin with subsequent resistance spread to cows.
Summary of assumptions
Key assumptions made in the model are presented below.
Most are conservative, that is, risk increasing.
 Ground beef is the major route of concern since path-
ogens in milk will be inactivated by pasteurization.
Whole cuts are infrequently contaminated and usually
cooked sufficiently. This assumption was consistent
with FDA guidance via personal communication.
 MDR Salmonella are similar to other Salmonella except
for the on-farm prevalence; the probability that a person
will get ill from contaminated ground beef; the proba-
bility that the ill person will seek medical attention and
be prescribed an antibiotic; and the probability that
persistent symptoms will occur. With the exception of
on-farm prevalence, all these parameters were increased
compared to other Salmonella.
 MDR Salmonella illness was modeled as more likely to
create illness and a doctor’s visit and antimicrobial
treatment.
 All foodborne Campylobacter have a 100% probability of
resistance development in treated animals; this is an
unrealistic but conservative assumption, due to lack of
data otherwise.
 Background sensitivity=susceptibility for all three bac-
terial types is 100%; that is, there is no background re-
sistance and all Salmonella or Campylobacter present in
treated animals or herdmates could develop resistance
due to enrofloxacin use.
 Fluoroquinolone-resistant Salmonella (excluding MDR)
or Campylobacter have the same likelihood of creating
illness as their susceptible counterparts.
 The number of illnesses resulting from consumption of
contaminated meat is roughly proportional to the
amount of contaminated meat consumed. No modeling
of dose–response relationships was directly included due
to lack of data on the doses presented to the consumer.
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The last assumption is similar to that used by FDA (FDA
CVM, 2000; Bartholomew et al., 2005) for the evaluation of the
impact on human health of fluoroquinolone-resistant Cam-
pylobacter attributed to the consumption of chicken. Although
there are other published modeling approaches, this risk in-
creasing assumption provides an upper bound on the esti-
mates (Cox, 2005). FDA evaluated the impact of historical
fluoroquinolone use in chickens and it was assumed that all
currently observed resistance to fluoroquinolones on the
carcasses of chickens was due to use of fluoroquinolones in
chickens. However, for this analysis, fluoroquinolones had
not been approved previously for use in dairy cattle intended
for milk production of any age. Therefore, current fluor-
oquinolone resistance in Campylobacter spp. and Salmonella
spp. could not be attributed to use of fluoroquinolones in
dairy heifers <20 months of age (Fig. 1).
Release
Node 1 (Table 1) is the initiating event of enrofloxacin
treatment of dairy heifers <20 months of age for respiratory
disease. Node 2 (Tables 2 and 3) is development of resistance
in Salmonella or Campylobacter residing within the treated
heifer, as a function of the bacterial prevalence and the
probability of resistance development in those bacteria. The
potential for resistant organisms to pass through the herd,
including milking cows, not just treated animals, through
commingling with treated dairy heifers was evaluated.
Commingling increases risk by increasing the number of an-
imals that may eventually carry resistant organisms or plas-
mids when heifers and cows go to market. Additionally, it
considers the possibility that herds receiving animals from
treated herds may be exposed to resistant bacteria after
commingling with the purchased animals. Output fromNode
2 is the number of live animals (cows and heifers) in treated
and untreated herds thatmay be carrying resistant organisms.
In Node 3 (Table 4) resistant bacteria leave the farm in cows or
heifers as they are culled to the slaughter market. In agree-
ment with FDA, milk was not considered as a release route, as
pasteurization will kill the bacteria of concern (Walstra et al.,
2006).
Exposure
In Node 4 (Table 5), viable resistant bacteria remain on the
carcass after slaughter. The output of Node 4 is the number
of carcasses contaminated with fluoroquinolone-resistant
organisms. Node 5 (Tables 6 and 7): the most likely route of
delivering resistant bacteria from beef carcasses through
processing, distribution, and preparation to the consumer is
through ground beef. Node 5 estimates the number of serv-
ings that will be contaminated with resistant bacteria deliv-
ered to the consumer fresh via retail or cooked via food
manufacturing, food service, and quick serve restaurants.
Other data that can be applied to this parameter for Salmonella
include the NARMS retail data. However, given the low
number of Salmonella and Campylobacter isolates, in this study,
NARMS data were considered as supplementary evidence
showing a very low probability of resistance development in
treated cattle. TheNARMS retail meat sampling data reported
only 19 Salmonella isolates and 1 Campylobacter isolate from
1522 ground beef samples in 2002 and 2003; none were re-
sistant to ciprofloxacin (FDA CVM, 2003b, 2003c).
Consequence
In Node 6 (Table 8) ground beef from meat that has not
been properly handled or prepared is consumed and causes
illness, and in Node 7 (Table 9) the ill person (18 years of age
and over) is treated with a fluoroquinolone-class antibiotic. In
Node 8 (Table 10) symptoms persist when human illness is
treated with a fluoroquinolone. The outcome of Nodes 6
Release : Resistant bacteria will develop and be released from farm due to enrofloxacin use 
N1: Enrofloxacin use on dairy heifers < 20 months of age 
: Resistance to FQs develops above background levelN2
N3: FQ-resistant pathogens leave farm 
Output: Live heifers and cows carrying FQ resistant pathogens, due to use of enrofloxacin in dairy heifers, at harvest
Exposure : Humans will be exposed to resistant bacteria released from the farm 
N4: Viable, FQ-resistant pathogens contaminate carcass after harvest 
N5: Viable, FQ-resistant pathogens remain in ground beef through processing, distribution, and 
 food preparation
Output: Servings of ground beef contaminated with FQ-resistant pathogens, due to use of enrofloxacin in dairy heifers - 
All food preparation establishments , including homes. (servings/year)
Consequence : Probability and magnitude of human health harm that might result from    
 resistant Campylobacter/Salmonella spp. 
N6: Human illness caused by consumption of ground beef contaminated with FQ-resistant  
  pathogens.
 N7: Human illness caused by consumption of ground beef contaminated with FQ-resistant  
  pathogens and treated with an FQ 
 N8: Adverse human health outcome occurs 
 Output: The probability of cases with persistent symptoms occurring on an annual basis to the average individual 18 years 
of age and over in the U.S. population
FIG. 1. Overview of model. Specific input=output details (parameters and distributions) are presented in Tables 1–10.
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through 8 is the number of cases of human illness where
persistent symptoms occurred after treatment with a fluor-
oquinolone and where illness was caused by consumption of
ground beef contaminated with fluoroquinolone-resistant
Campylobacter or Salmonella due to use of enrofloxacin in dairy
heifers <20 months of age.
Sensitivity analysis was performed to estimate the effect of
uncertainty of some assumptions on the final results. Three
parameters were evaluated by running 27 alternative sce-
narios for each bacteria using high, medium, and low esti-
mates for each parameter. These included (1) Node 2,
combinations of observed resistance to fluoroquinolones in
animals treated with enrofloxacin (% of positive animals
carrying resistant isolates), Campylobacter (100%, 75%, and
50%), Salmonella, and MDR Salmonella (100%, 20%, and 2%)
with observed resistance to fluoroquinolones in animals not
treated with enrofloxacin (% of positive animals carrying re-
sistant isolates) Campylobacter (20%, 15%, and 10%), Salmo-
nella, andMDR Salmonella (16.8%, 3.3%, and 0.3%); (2) Node 6,
the ratio of illnesses attributed to beef per contaminated
serving of ground beef after food preparation, Campylobacter
(0.0062, 0.0005, and 0.0028), Salmonella (0.0324, 0.0056, and
0.0165), and MDR Salmonella (0.3284, 0.0566, and 0.1656); and
(3) Node 8, probability that symptoms persist when human
illness is treated with a fluoroquinolone for each parameter,
Campylobacter, Salmonella, and MDR Salmonella (100%, 10%,
36%). The alternative scenarioswere run using baseline values
for all other parameters in the model.
Results
Table 11 summarizes the estimated risk of fluoroquinolone
treatment failure (persistent symptoms) in humans treated for
foodborne diseases resulting from consumption of ground
beef originating from dairy heifers treated with enrofloxacin.
Results are reported in two forms: expected frequency of a
treatment failure case in the at risk population (18 years and
older) and probability of the event happening to the average
person in that population.
Baseline and worst-case scenario results are based on
conditions and population assumptions at the time of the
analysis.
Baseline scenarios
For Campylobacter the model predicts that on average one
case of persistent symptomswould occur every 13 years using
the baseline scenario. The mode for all simulations was one
case every 18 years; 50% of all simulations predicted a risk of
less than the mode. The 95% confidence interval on this dis-
tribution was one case every 38.3 years to every 6.5 years. The
left skewed distribution shows that there is a remote chance of
one case every 4 years for the baseline scenario.
For Salmonella the model predicts that one case of persistent
symptomswould occur every 293 years, on average, using the
baseline scenario. The mode for all simulations was one case
every 501.2 years. The 95% confidence interval on this distri-
bution was one case every 129.3 to every 1060.8 years.
Table 1. Release Node 1
Node 1: enrofloxacin used in dairy heifers< 20 months of age
Herds with dairy heifers only Herds with dairy cows and dairy heifers
Campylobacter Salmonella
MDR
Salmonella Campylobacter Salmonella
MDR
Salmonella Reference
Input
(a) Number of
herds (no
distribution
was used)
1,629 1,629 1,629 79,811 79,811 79,811 USDA NASS
(2005a),
USDA
NAHMS
(2002, 2005),
DRMS (2006)
(b) Percentage
of herds in
which dairy
heifers may be
treated with
enrofloxacin
(no distribution
was used)
25% 25% 25% 19% 19% 19% DMR (2005),
USDA
NAHMS
(2005)
Model output
Number of herds
in which
enrofloxacin
may be used
to treat
dairy heifers
407 407 407 15,008 15,008 15,008 Model calculation:
(a)(b)
Forward results
to Node 2
(Table 2)
MDR, multidrug resistant.
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Table 5. Exposure Node 4
Node 4: viable, fluoroquinolone-resistant pathogens contaminate carcass after harvest
Campylobacter Salmonella MDR Salmonella Reference
Input
(a) Live dairy heifers and cows car-
rying fluoroquinolone-resistant
pathogens due to use of enro-
floxacin in dairy heifers at har-
vest (head=year)
59,985 449 39 Output from Node 3 (Table 4)
(b) Probability a carcass from a live
animal, whether carrying patho-
gens or not, becomes contami-
nated with pathogen
0.012 0.012 0.012 USDA FSIS (1994, 2006)
Model output
Carcasses contaminated with fluoro-
quinolone-resistant pathogens due to
use of enrofloxacin in dairy heifers
(carcasses=year)
711.1 5.3 0.5 Model calculation: (a)(b)
(note: numbers not exact as
model rounds throughout
calculation)
Forward results to Node 5a
(Table 6)
Table 6. Exposure Node 5
Node 5a: viable, fluoroquinolone-resistant pathogens remain in ground beef through processing, distribution, and food preparation
Campylobacter Salmonella MDR Salmonella Reference
(a) Carcasses contaminated with fluoroquino-
lone-resistant pathogens due to use of
enrofloxacin in dairy heifers (carcasses=-
year)
711.1 5.3 0.5 Output from Node 4
(Table 5)
(b) Probability that ground beef from a carcass
contaminated with pathogens is contami-
nated
1 1 1 NAS (2002)
(c) Multiplier due to mixing of meat from
carcasses contaminated by pathogens with
that of noncontaminated carcasses
2.00 2.00 2.00 J. Dickson (pers. comm.)
(d) Average dressed carcass weight (kg=car-
cass)
285 285 285 Rogers (2004)
(e) Percentage of carcass that is processed into
ground beef
80% 80% 80% Roberts (1999)
(f ) Quantity of ground beef from carcasses (kg) 324,241 2,414 211 Model calculation:
(a)(b)(c)(d)(e)
(g) Percentage of ground beef from carcasses
that is distributed to quick service restau-
rants
58% 58% 58%
(h) Percentage of ground beef from carcasses
that is distributed to manufacturing
5% 5% 5% NCBA (2004)
(I) Percentage of ground beef from carcasses
that is distributed to food service
34% 34% 34%
(j) Percentage of ground beef from carcasses
that is distributed to retail=home con-
sumption
3% 3% 3%
Quantity of ground beef from carcasses dis-
tributed to quick serve restaurants (kg=year)
188,060 1,400 122 Model calculation:
(f )(g)
Quantity of ground beef from carcasses dis-
tributed to manufacturing (kg=year)
16,212 121 11 Model calculation:
(f )(h)
Quantity of ground beef from carcasses dis-
tributed to food service (kg=year)
110,242 821 72 Model calculation:
(f )(i)
Quantity of ground beef from carcasses dis-
tributed to retail=home consumption (kg=year)
9,727 72 6 Model calculation:
(f )(j)
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For MDR Salmonella the model predicts that one case of
persistent symptoms would occur every 158 years, on aver-
age, using the baseline scenario. The mode for all simulations
was less than one case every 292 years. The 95% confidence
interval on this distribution was one case every 67.8–647.2
years.
Worst-case scenarios
Worst-case scenarios are reportedwhere all treated animals
develop resistance, where underreporting, attribution, and
carcass contamination are at their maximum, and where the
probability of persistent symptoms in treated patients
is 100%.
The worst-case scenario for Campylobacter estimates a
mean risk of only one case every 2.2 years. The upper-bound
(95th percentile) estimate from the worst-case scenario shows
that one case of persistent symptoms might occur every
1.1 years, a risk of 1 in 210 million and qualitatively describ-
able as ‘‘very low.’’
The worst-case scenario for Salmonella estimates a mean
risk of one case every 1.4 years. The upper-bound (95th per-
centile) estimate from the worst-case scenario shows one case
of persistent illness every 0.7 years
The worst-case scenario for MDR Salmonella estimates a
mean risk of one case every 0.8 years. The upper-bound (95th
percentile) estimate from the worst-case scenario shows one
case of persistent illness every 0.4 years.
Discussion
Multiple conservative, parameter estimations were used
throughout the model. Some of the parameters, such as
attribution (Node 6), resistance development in untreated
herd mates (Node 2), and probability of persistent symptoms
(Node 8), should be at or near zero. Unrealistically, this model
did not place much of the probability density near zero.
Therefore, themean frequency baseline results shown in Table
11 should be viewed as upper bounds on the risk or worst
case.
Additionally, themultiple scenarios simulated showed that
even with all the worst case and unlikely assumptions we
made, the risks were very low. For example, the worst case
assumes that MDR Salmonella would always (100%) develop
resistance in treated heifers, are 10 times more likely to cause
human illness, and would always (100%) produce persistent
symptoms in treated patients. Clearly, these are unrealis-
tic assumptions, especially given the low to zero levels of
ciprofloxacin resistance being reported by NARMS after
Baytril100 use in beef cattle since 1999 (FDA CVM, 2003c).
The sensitivity analysis showed that results were most
sensitive to changes in Node 6 (Ratio of Illnesses Attributed to
Table 8. Consequence Node 6
Node 6: human illness caused by consumption of ground beef contaminated with fluoroquinolone-resistant pathogens
Campylobacter Salmonella MDR Salmonella Reference
Input
(a) Servings of ground beef con-
taminated with fluoroquinolone-re-
sistant pathogens due to use of
enrofloxacin in dairy heifers—all
food preparation establishments
(servings=year)
1,728 13 1 Output from Node 5 (Table 7)
(b) Ratio of illnesses attributed to
beef per contaminated serving of
ground beef after food preparation.
Ratio was simulated in a separate
spreadsheet used to perform a sep-
arate Monte Carlo simulation to
estimate a distribution for this ratio.
The distribution was then sampled
to run the main model. Values
shown are means of the distribution.
0.0028 0.0165 0.1656 USDA NASS (2004, 2005b), USDA
FSIS (1994, 2006), J. Dickson (pers.
comm..), Rogers (2004), USDA ERS
(2006), Roberts (1999), Census Bu-
reau (2002), Flint et al. (2005), Mead
et al. (1999), Altekruse et al. (1999),
CDC (1990–2004, 2003), Wheeler
et al. (1999), Samuel et al. (2004),
Friedman et al. (2004), de Wit et al.
(2000), Flint et al. (2005), Voetsch
et al. (2004), Rocourt et al. (2003),
Danish Zoonoses Centre (2003),
Champion et al. (2005), FDA CVM
(2003b), Nielsen et al. (2006),
Hald et al. (2004)
Model output
Number of human illness cases
caused by consumption of ground
beef contaminated with fluoroqui-
nolone-resistant pathogens due to
use of enrofloxacin in dairy heifers
(U.S. cases=year)
4.84 0.21 0.19 Model calculation: (a)(b)
Forward results to Node 7 (Table 9)
FDA, Food and Drug Administration.
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Table 9. Consequence Node 7
Node 7: human illness caused by consumption of ground beef contaminated with fluoroquinolone-resistant pathogens
is treated with a fluoroquinolone
Campylobacter Salmonella MDR Salmonella Reference
Input
(a) Cases of human illness
caused by consumption
of ground beef contami-
nated with fluoroquino-
lone-resistant pathogens
due to use of enrofloxacin
in dairy heifers (U.S.
cases=year)
4.84 0.21 0.19 Output from Node 6 (Table 8)
(b) Probability the patient
seeks medical help
0.17 0.17 0.28 FDA CVM (2000), Herikstad
et al. (2002), de Wit (2000),
Wheeler et al. (1999), McNulty
(1987), Hurd (2004), Voetsch
et al. (2004), Molbak et al.
(1999), Dechet et al. (2006)
(references used to create a
triangular distribution in @Risk:
[min, most likely, max])
(5%,15%,30%) (5%,15%,30%) (5%,30%,50%)
(c) Probability an antimicro-
bial is prescribed and the
antimicorbial is a fluoro-
quinolone
0.27 0.27 0.33 FDA CVM (2000), de Wit et al.
(2000), Wistrom (1995), Tabi-
bian et al. (1987), Chan et al.
(2003), CDC MMWR (2004),
Allos (2001), Molbak et al.
(1999), Dechet et al. (2006)
(references used to create a
triangular distribution in @Risk:
[min, most likely, max])
(10%,20%,50%) (10%,20%,50%) (10%,30%,60%)
Model output
(d) Cases of human illness
treated with a fluoroqui-
nolone, caused by con-
sumption of ground beef
contaminated with fluor-
oquinolone-resistant
pathogens due to use of
enrofloxacin in dairy
heifers (U.S. cases=year)
0.215 0.009 0.018 Model calculation: (a)(b)(c)
(note: model rounds)
Forward results to Node 8
(Table 10)
(e) U.S. 2000 Census popula-
tion of persons old en-
ough to be treated for
foodborne illness with an
antimicrobial (persons 18
years of age and over)
209,128,094 Census Bureau (2002)
The rate of illness occurring on
an annual basis to the average
individual 18 years of age and
over in the U.S. population
(illnesses=1,000,000,000)
1.028 0.045 0.084 Model calculation:
(d)=[(e)=1,000,000.000]
The probability of illness oc-
curring on an annual basis to
the average individual 18 years
of age and over in the U.S.
population
0.0000000010 0.000000000045 0.0000000001 Model calculation: (d)=(e)
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Beef per Contaminated Serving of Ground Beef Following
Food Preparation). Assumptions made about the portion of
all foodborne illness attributable to a specific commodity
should be made carefully. This finding is not surprising given
that this one parameter reflects many illness impacting pro-
cesses such as handling, cooking, and bacterial dose. Ad-
ditionally, the importance of this parameter demonstrates the
important role of standard food hygiene practices in reducing
antibiotic resistance risk. Risk would increase if there were to
be a highly virulent and prevalent pathogen whose source
was predominately meat.
The approach used in Node 6 (Table 8) relies upon what
is observed and known about the level of foodborne illness
attributed to ground beef relative to the estimated number of
servings of ground beef that were contaminated with each of
the foodborne pathogens modeled. It assumes that the num-
ber of illnesses resulting from consumption of contaminated
meat is roughly proportional to the amount of contaminated
meat consumed if the level of contamination is held fixed
(Bartholomew et al., 2005). Key processes between the farm
and the consumer were modeled to project the relative
increase in the number of servings of ground beef contami-
Table 10. Consequence Node 8
Node 8: adverse human health outcome occurs
Campylobacter Salmonella MDR Salmonella Reference
Input
(a) Cases of human illness
treated with a fluoroqui-
nolone, caused by con-
sumption of ground beef
contaminated with fluor-
oquinolone-resistant
pathogens due to use of
enrofloxacin in dairy
heifers (U.S. cases=year)
0.2151 0.0094 0.0176 Output from Node 7 (Table 9,
row [d])
(b) Probability that symp-
toms persist when human
illness is treated with a
fluoroquinolone
0.36 0.36 0.36 Kuschner et al. (1995), Sirina-
vin and Garner (2000), Wis-
trom (1992, 1995), Dryden
et al. (1996), Nelson et al.
(2004), Sanders et al. (2002)
Output
(c) Cases of human illness
where symptoms persist
after treatment with a
fluoroquinolone and
where illness was caused
by consumption of
ground beef contami-
nated with fluoroquino-
lone-resistant pathogen
due to use of enrofloxacin
in dairy heifers (U.S.
cases=year)
0.077 (1 case ev-
ery 13 years)
0.003 (1 case ev-
ery 294.4 years)
0.006 (1 case ev-
ery 158.1 years)
Model calculation: (a)(b)
(d) U.S. 2000 Census popu-
lation of persons old en-
ough to be treated for
foodborne illness with an
antimicrobial (persons 18
years of age and over)
209,128,094 Census Bureau (2002)
The rate of persistent symptoms
occurring on an annual basis to
the average individual 18 years
of age and over in the U.S.
population (ill-
nesses=1,000,000,000)
0.370 0.016 0.030 Model calculation:
(c)=[(d)=1,000,000,000]
The probability of cases with
persistent symptoms occurring
on an annual basis to the aver-
age individual 18 years of age
and over in the U.S. population
1 in 2702 million 1 in 61566 million 1 in 33053 million Model calculation:
(1=[(c)=(d)])=1,000,000
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nated by fluoroquinolone-resistant Campylobacter, Salmonella,
or MDR Salmonella. The ratio of illnesses attributed to beef per
contaminated serving of ground beef after food preparation is
modeled in a separate spreadsheet used to perform a separate
Monte Carlo simulation to estimate a distribution for this
ratio. The distribution was then sampled to run the main
model.
We do not distinguish among different levels of contam-
ination (e.g., 1 CFU per ton, whichmight cause no harm, vs. 1
billion CFUs per oz, which presumably would bemuchmore
hazardous). In reality, it is plausible that average levels of
contamination cause little or no harm, and that our estimates
are upper bounds, driven by occasional pockets of high
concentrations, rather than by average levels of contam-
ination.
The purpose of Node 1was to estimate the number of dairy
operations where Baytril100 would be used if approved for
respiratory disease treatment in dairy heifers <20 months of
age. It is important to understand the structure of the U.S.
dairy industry and the management of replacement heifers to
understand the potential risk of Baytril100 use in dairy re-
placement heifers; heifers are raised to enter the milking herd,
not the food chain. Very few dairy heifers are sold for
slaughter because of their value for milk production and
breeding. Most illness and treatment occurs during the first
fewmonths of life, long before they begin milking. Heifers are
commingled with others of similar age and are sometimes
sold to other farms. Heifers are often kept in separate facilities
from milking cows until the time of their first calving when
milking begins.
MDR serovars of Salmonella such as Newport and Typhi-
murium DT104 are of concern to human health for two rea-
sons. They are thought more likely to acquire resistance to
antibiotics like enrofloxacin and to cause human illness that is
difficult to treat. To address these concerns, it was assumed
that any MDR Salmonella would have a higher probability of
resistance acquisition on-farm. Additionally, two other pa-
rameters were increased compared to nonresistant Salmonella:
the probability that an ill patient will seek medical attention
and the probability that an antibiotic will be prescribed
(Node 7).
Uniquely, this model considers not only the development
of resistance in treated herds, but also the transfer of resistant
bacteria or genetic determinants through the movement of
cattle to operations that are not using enrofloxacin.Othermodels
focus on resistance development in treated animals only.
Our model focused on foodborne transmission of fluor-
oquinolone-resistant Salmonella and Campylobacter via ground
beef. Routes of transmission other than foodborne were not
considered in the model because the majority of dairy cattle
meat goes into ground beef and pasteurization eliminates
pathogens in milk (NCBA, 2004; Walstra et al., 2006).
Quantitative risk assessment is a widely used method to
evaluate the probability of specific hazards and guide policy
decisions. For this model we used an event tree approach that
allowed inclusion of stochastic elements to account for bio-
logical variability and uncertainty for key parameters. Mod-
els, quantitative or qualitative, always have weaknesses. The
key question is whether these weaknesses consistently over-
or underestimate (bias) the risk. We used several approaches
to insure that the model results would represent conservative
(higher) risk estimates, to evaluate the effect of parameters for
which little scientific data were available and to account for
indirect transmission pathways.
This study was conducted to fulfill CVM’s requirement to
complete a risk assessment for all new antimicrobial products
and uses. The model presented in this article takes into
account any potential resistant organisms introduced into the
dairy herd from treated heifers, including spread through
commingling with the potential of entering the food supply
from slaughtered dairy cows.
While FDA GD 152 recommends a qualitative risk assess-
ment approach, the ‘‘FDA does not intend to exclude quan-
titative risk assessment in favor of a qualitative process’’ (FDA
CVM, 2003a). The qualitative risk of using injectable antimi-
crobials in treating individual food-producing animals is in-
herently low. When reliable information is available, the use
of a quantitative model allows a detailed study of multiple
risk factors. Since fluoroquinolones are considered critically
important to human health, the merging of quantitative esti-
mates with qualitative classifications allows reviewers to gain
additional insight into the magnitude of qualitative risk
classifications.
Conclusions
Mean annual risk estimates of 1 in 2.8 billion, 61.4 billion,
and 33.1 billion for Campylobacter, Salmonella, and MDR
Salmonella, respectively, can be considered qualitatively very
low. These estimates are arguably conservative and upper-
bounded due to the multiple conservative parameter esti-
mates incorporated into the model such as the inclusion of
resistance spread to commingled and untreated herd mates,
the potential movement of resistance bacteria with sold dairy
heifers, and the mixing of ground beef. This modeled risk is
hypothetical and the actual risk could well be even lower.
Table 11. Predicted Case Frequency and Probability of Persistent Symptoms of Foodborne Disease
in an Average Individual 18 Years of Age and Over in the United States, Treated with Fluoroquinolones,
After Consumption of Ground Beef Containing Foodborne Pathogen(s) Originating
from Dairy Heifers (<20 Months of Age) Treated with Enrofloxacin
Campylobacter Salmonella MDR Salmonella
Mean Case frequency 1 every 13.2 years 1 every 293.4 years 1 every 157.9 years
Probability 1 in 2.8 billion 1 in 61.4 billion 1 in 33.1 billion
Mode Case frequency 1 every 18.2 years 1 every 501.2 years 1 every 292 years
Probability 1 in 3.8 billion 1 in 104.9 billion 1 in 61.1 billion
95% prediction interval Case frequency (6.5–38.3) years (129.3–1,060.8) years (67.8–647.2) years
Probability (1.4–8) billion (27.1–221.9) billion (14.2–135.4) billion
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